What is OS Therapies's royalty net sales pecentage?

OS Therapies (OSTX) reported royalty net sales pecentage of 6% in Q1 2026.

What does royalty net sales pecentage mean?

The contractual rate applied to net product sales to determine royalty payments owed to third-party licensors. This metric is critical for understanding the long-term margin impact of intellectual property licensing.

OS Therapies OSTX Royalty Net Sales Pecentage

Royalty Net Sales Pecentage at other companies

BalchemBCPC

$493K+7.6%

Ultragenyx PharmaceuticalRARE

30%—

ZymeworksZYME

2.5%—

Ondas, Inc. ONDS

3%0.0pp

SharkNinjaSN

$3.33M-30.5%

Sutro BiopharmaSTRO

4%0.0pp

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept osti:RoyaltyNetSalesPecentage.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's royalty net sales pecentage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's royalty net sales pecentage?: OS Therapies (OSTX) reported royalty net sales pecentage of 6% in Q1 2026.
What does royalty net sales pecentage mean?: The contractual rate applied to net product sales to determine royalty payments owed to third-party licensors. This metric is critical for understanding the long-term margin impact of intellectual property licensing.